Supplementation with L-arginine favorably influences plasminogen activator inhibitor type 1 concentration in obese patients. A randomized, double blind trial

Journal of Endocrinological Investigation

Volumn 36, Issue 4, 2013, Pages 221-226

  Bogdanski, P ^a   Szulinska, M ^a   Suliburska, J ^b   Pupek Musialik, D ^a   Jablecka, A ^a   Witmanowski, H ^a,c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

^c NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Insulin sensitivity; L arginine; Obesity; Oxidative stress; PAI 1

Indexed keywords

ARGININE; NITRIC OXIDE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ANTHROPOMETRY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INSULIN SENSITIVITY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OBESITY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIOXIDANTS; ARGININE; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; NITRIC OXIDE; OBESITY; OSMOLAR CONCENTRATION; PLACEBOS; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 84878976899     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8467     Document Type: Article

References (40)

1. Flegal K, Carroll M, Ogden C, Curti L. Prevalence and trends in obesity among US adults". JAMA 2010, 303: 235-41.
2. Abdullah A, Wolfe R, Stoelwinder J, et al. The number of years lived with obesity and the risk of all-cause and cause-specific mortality. Int J Epidemiol 2011, 40: 985-96.
3. King VL, Hatch NW, Chan HW, de Beer MC, de Beer FC, Tannock LR. A murine model of obesity with accelerated atherosclerosis. Obesity 2010, 18: 35-41.
4. Meyers MR, Gokce N. Endothelial dysfunction in obesity: etiological role in atherosclerosis. Curr Opin Endocrinol Diabetes Obes 2007, 14: 365-9. (Pubitemid 47368087)
5. Fernández-Sánchez A, Madrigal-Santillán E, Bautista M, et al. Inflammation, oxidative stress, and obesity. Int J Mol Sci 2011, 12: 3117-32.
6. Viitanen L, Pihlajamäki J, Halonen P, Lehtonen M, Kareinen A, Lehto S. Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease. Atherosclerosis 2001, 157: 57-64. (Pubitemid 32539354)
7. Ihara H, Urano T, Takada A, Loskutoff D. Induction of plasminogen activator inhibitor 1 gene expression in adipocytes by thiazolidinediones. FASEB J 2001, 15: 1233-5.
8. Voros G, Maquoi E, Collen D, Lijnen H. Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-alpha, TNF-alpha converting enzyme and ADAMTS family members in murine fat territories. Biochim Biophys Acta 2003, 1625: 36-42. (Pubitemid 36084501)
9. Correia ML, Haynes WG. A role for plasminogen activator inhibitor-1 in obesity: from pie to PAI? Arterioscler Thromb Vasc Biol 2006, 26: 2183-5. (Pubitemid 44465709)
10. Vaughan D. PAI-1 and atherothrombosis. J Thromb Haemost 2005, 3: 1879-83. (Pubitemid 41716575)
11. Morange PE, Saut N, Alessi MC, et al. Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study. Arterioscler Thromb Vasc Biol 2007, 27: 2250-7. (Pubitemid 350287257)
12. Knudsen EC, Seljeflot I, Abdelnoor M. Elevated levels of PAI-1 activity and t-PA antigen are associated with newly diagnosed abnormal glucose regulation in patients with ST-elevation myocardial infarction. J Thromb Haemost 2011, 9: 1468-74.
13. Festa A, D'Agostino R, Tracy R, Haffner S. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2002, 51: 1131-7. (Pubitemid 34438360)
14. Chen B, Lam KS, Wang Y, et al. Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. Biochem Biophys Res Commun 2006, 341: 549-56. (Pubitemid 43152139)
15. Miyagawa R, Asakura T, Nakamura T, et al. Increased expression of plasminogen activator inhibitor type-1 (PAI-1) in HEPG2 cells induced by insulin mediated by the 3′-untranslated region of the PAI-1 gene and its pharmacologic implications. Coron Artery Dis 2010, 21: 144-50.
16. Dimova EY, Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver. Thromb Haemost 2008, 100: 992-1006.
17. Marik P, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009, 32: 365-72.
18. Hill A, Fleming J, Kris-Etherton P. The role of diet and nutritional supplements in preventing and treating cardiovascular disease. Curr Opin Cardiol 2009, 24: 433-41.
19. Böger R. L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous? Curr Opin Clin Nutr Metab Care 2008, 11: 55-61. (Pubitemid 350295228)
20. Cable D, Celotto A, Evora P, Schaff H. Asymmetric dimethylarginine endogenous inhibition of nitric oxide synthase causes differential vasculature effects. Med Sci Monit 2009, 15: 248-53.
21. Loscalzo J. L-Arginine and Atherothrombosis. J Nutr 2004, 134: 2798-800.
22. Siasos G, Tousoulis D, Antoniades C, Stefanadi E, Stefanadis C. L-Arginine, the substrate for NO synthesis: an alternative treatment for premature atherosclerosis? Int J Cardiol 2007, 116: 300-8. (Pubitemid 46283019)
23. Gokce N. L-Arginine and Hypertension. J Nutr 2004, 134: 2807-11.
24. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237: E214-23. (Pubitemid 9249478)
25. Di Gregorio GB, Westergren R, Enerback S, Lu T, Kern PA. Expression of FXC2 in adipose and muscle and its association with whole body insulin sensitivity. M J Physiol Endocrinol Metab 2004, 287: E799-803. (Pubitemid 39237911)
26. Ferroni P, Guagnano MT, Manigrasso MR, Ciabattoni G, Davi G. Increased plasminogen activator inhibitor-1 levels in android obesity: correlation between oxidative stress. J Thromb Haemost 2005, 3: 1086-7. (Pubitemid 41632842)
27. Wingeyer SD, Graffigna MN, Belli SH, Benetucci J, de Larrañaga GF. Role of -675 4G/5G in the Plasminogen Activator Inhibitor-1 Gene and -308G/A Tumor Necrosis Factor-α Gene Polymorphisms in Obese Argentinean Patients. Genet Test Mol Biomarkers 2012, 16: 372-5.
28. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000, 11: 327-32.
29. Demircan N, Gurel A, Armutcu F, Unalacak M, Aktunc E, Atmaca H. The evaluation of serum cystatin C, malondialdehyde, and total antioxydant status in patients with metabolic syndrome. Med Sci Monit 2008, 14: CR97-101.
30. Qiao LY, Goldberg JL, Russell JC, Sun XJ. Identification of enhanced serine kinase activity in insulin resistance. J Biol Chem 1999, 274: 10625-32.
31. King G, Goodmann D, Buzney S. Receptors and growth promoting effects of insulin and insulin-like growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest 1985, 75: 1028-36. (Pubitemid 15115273)
32. Piatti PM, Monti LD, Valsecchi G. Long-term oral l-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care 2001, 24: 875-80. (Pubitemid 33636062)
33. Habib S, Ali A. Biochemistry of nitric oxide. J Clin Biochem 2011, 26: 3-17.
34. Miller-Kasprzak E, Bogdański P, Pupek-Musialik D, Jagodziński PP. Insulin resistance and oxidative stress influence colony-forming unit-endothelial cells capacity in obese patients.Obesity 2011, 19: 736-42.
35. Palomo I, Contreras A, Alarcón LM, et al. Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome. Nitric Oxide 2011, 24: 224-8.
36. Kowalski J, Sliwczyńska-Rodziewicz D, Kowalczyk E, et al. Plasma nitric oxide and vascular endothelial growth factor levels in patients with metabolic syndrome and co-existing vascular complications. Pol Merkur Lekarski 2011, 30: 249-52.
37. Jablecka A, Checinski P, Krauss H, Micker M, Ast J. The influence of two different doses of L-arginine oral supplementation on nitric oxide (NO) concentration and total antioxidant status (TAS) in atherosclerotic patients. Med Sci Monit 2004, 10: 29-32.
38. Balon TB, Nadler JB. Evidence that nitric oxide increases glucose transport in skeletal muscle. J Appl Physiol 1997, 82: 359-63.
39. Young M, Leighton B. Evidence for alterated sensitivity of nitric oxide/cGMP signaling cascade in insulin resistant skeletal muscle. Biochem J 1998, 329: 73-9. (Pubitemid 28022292)
40. Monti LD, Valsecchi G, Costa S. Effects of endothelin 1 and nitric oxide on glucokinase activity in isolated rat hepatocytes. Metabolism 2000, 49: 73-80. (Pubitemid 30054036)